Yahoo · Oct 30, 2026
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
VTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?
EL
NASDAQ · ELAN
Elanco Animal Health Incorporated
Healthcare · Drug Manufacturers - Specialty & Generic
$23.06
Down-$0.18 (-0.77%)
Updated Nov 2, 2026, 9:12 AM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 10.58B
- P/E ratio
- 293.94
- Dividend yield
- 0.00%
- 52-week range
- $19.40 – $27.98
- Volume
- 3.45M
- Avg. volume
- 5.48M
Price performance · ELAN
ELAN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ELAN closed at $23.06 after 20 trading sessions, up 2.44% for the selected period.
- Last close
- $23.06
- Period change
- +2.44%
- Period low
- $22.36
- Period high
- $23.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $23.48 | $23.48 | $22.93 | $23.06 | 3.45M |
| Oct 29, 2026 | $22.84 | $23.25 | $22.775 | $23.24 | 3.49M |
| Oct 28, 2026 | $22.75 | $22.92 | $22.56 | $22.65 | 4.39M |
| Oct 27, 2026 | $22.91 | $23.19 | $22.595 | $22.65 | 4.99M |
| Oct 26, 2026 | $22.62 | $23.095 | $22.18 | $22.96 | 4.21M |
| Oct 23, 2026 | $22.44 | $22.76 | $22.31 | $22.52 | 4.28M |
| Oct 22, 2026 | $22.43 | $22.8423 | $22.35 | $22.69 | 4.45M |
| Oct 21, 2026 | $22.975 | $22.975 | $22.23 | $22.55 | 4.86M |
| Oct 20, 2026 | $23.29 | $23.47 | $22.03 | $22.70 | 8.25M |
| Oct 19, 2026 | $23.71 | $23.96 | $23.45 | $23.49 | 2.9M |
| Oct 16, 2026 | $23.87 | $24.11 | $23.41 | $23.55 | 5.17M |
| Oct 15, 2026 | $22.83 | $23.79 | $22.80 | $23.54 | 6.65M |
| Oct 14, 2026 | $22.38 | $22.92 | $22.2647 | $22.55 | 4.94M |
| Oct 13, 2026 | $22.63 | $22.77 | $22.22 | $22.41 | 3.35M |
| Oct 12, 2026 | $22.88 | $22.93 | $22.55 | $22.56 | 4.65M |
| Oct 9, 2026 | $22.59 | $22.975 | $22.42 | $22.92 | 2.52M |
| Oct 8, 2026 | $22.08 | $22.625 | $22.00 | $22.54 | 4.57M |
| Oct 7, 2026 | $22.26 | $22.62 | $22.16 | $22.36 | 4.2M |
| Oct 6, 2026 | $22.72 | $23.04 | $22.23 | $22.48 | 7.04M |
| Oct 5, 2026 | $22.09 | $22.725 | $21.72 | $22.51 | 4.79M |
Latest ELAN news
The latest Smart Investors Daily articles mentioning ELAN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ELAN research
Overview
Company profile and research snapshot.
Company profile
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $24.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | Equal-Weight | — |
| Oct 20, 2026 | Jefferies | Hold | — |
| Oct 16, 2026 | Goldman Sachs | Buy | — |
| Aug 6, 2026 | Keybanc | Overweight | — |
| Aug 6, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga · Oct 29, 2026
Morgan Stanley Maintains Equal-Weight on Elanco Animal Health, Lowers Price Target to $25
Morgan Stanley analyst Erin Wright maintains Elanco Animal Health (NYSE:ELAN) with a Equal-Weight and lowers the price target from $26 to $25.
Yahoo · Oct 28, 2026
Encompass Health (EHC) Q3 Earnings and Revenues Top Estimates
Encompass Health (EHC) delivered earnings and revenue surprises of +10.15% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
